Real World Outcomes with Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody: A Single Center Experience for Relapsed/ Refractory Multiple Myeloma (RRMM)

被引：0
|
作者：
Gill, Sarvarinder Kaur [1 ]
Fleming, Erika [2 ]
Gebre, Helen [1 ]
Bangolo, Ayrton, I [3 ]
Siegel, David S. [4 ,5 ]
Vesole, David H. [6 ]
Biran, Noa [6 ]
Parmar, Harsh [6 ]
Phull, Pooja [6 ]
机构：
[1] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[2] Hackensack Meridian Sch Med, Nutley, NJ USA
[3] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Edgewater, NJ USA
[4] Hackensack Meridian Hlth, John Theurer Canc Ctr, Div Multiple Myeloma, Hackensack, NJ USA
[5] Ctr Discovery & Innovat, Hackensack, NJ USA
[6] Hackensack Univ Med Ctr, Div Multiple Myeloma, John Theurer Canc Ctr, Hackensack, NJ USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-210350
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7047 / 7048
页数：2
相关论文
共 50 条
  • [41] Anti-BCMA/GPRC5D bispecific CART cells in patients with relapsed or refractory multiple myeloma: a single-arm single-centre, phase 1 trial
    Zhou, Dian
    Sun, Qian
    Xia, Jieyun
    Gu, Weiying
    Qian, Jun
    Zhuang, Wanchuan
    Yan, Zhiling
    Cheng, Hai
    Chen, Wei
    Zhu, Feng
    Qi, Kunming
    Li, Depeng
    Sang, Wei
    Zhu, Lili
    Ma, Sha
    Li, Hujun
    Zhang, Huanxin
    Qiu, Tingting
    Yan, Dongmei
    Zhang, Yanlei
    Peng, Shuixiu
    Chang, Alex H.
    Xu, Kailin
    Li, Zhenyu
    LANCET HAEMATOLOGY, 2024, 11 (10): : e751 - e760
  • [42] Dermatological toxicities induced by T-cell-redirecting G protein-coupled receptor family C class 5 member D bispecific antibody talquetamab
    Lery, Marion
    Perrot, Aurore
    Ortiz-Brugues, Ariadna
    Vigarios, Emmanuelle
    Anghel, Diana
    Bories, Pierre
    Sibaud, Vincent
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (02) : 376 - 377
  • [43] Bispecific and trispecific GPRC5D antibodies with potent cell-killing activity against multiple myeloma
    Roth, Hayley
    Rogers, Daniel
    Sanchez, Ileine
    Tyrell, Breanna
    Barnes, Trevor
    Snyder, Ami
    Nowgu, Nenna
    Doolan, Kyle
    Doranz, Benjamin J.
    Chambers, Ross
    Rucker, Joseph B.
    CANCER RESEARCH, 2024, 84 (06)
  • [44] Taste Abnormalities Emerging during Anti- Myeloma Therapies Including GPRC5D x CD3 Bispecific Antibody Talquetamab
    Fleischer, Anna
    Roll, Magdalena
    Panther, Franziska
    Gelbrich, Goetz
    Reinhardt, Franziska
    Riedhammer, Christine
    Mersi, Julia
    Waldschmidt, Johannes M.
    Einsele, Hermann
    Kortuem, K. Martin
    Maatouk, Imad
    Rasche, Leo
    BLOOD, 2023, 142
  • [45] Mechanisms of Resistance and Determinants of Response of the GPRC5D-Targeting T-Cell Redirecting Bispecific Antibody JNJ-7564 in Multiple Myeloma
    Verkleij, Christie P. M.
    Broekmans, Marloes
    Wong, Amy
    Zweegman, Sonja
    Verona, Raluca
    Adams, Homer, III
    Mutis, Tuna
    van de Donk, Niels W. C. J.
    BLOOD, 2020, 136
  • [46] REAL-WORLD EXPERIENCE OF LENALIDOMIDE/DEXAMETHASONE TREATMENT FOR REFRACTORY/RELAPSED MULTIPLE MYELOMA (RRMM) PATIENTS
    Tognazzi, L.
    Rivolti, E.
    Quaresima, M.
    Labbozzetta, S.
    Gamberi, B.
    Merli, F.
    HAEMATOLOGICA, 2017, 102 : 137 - 137
  • [47] Real World Outcomes with Elotuzumab-Based Therapies for Patients with Relapsed Refractory Multiple Myeloma (RRMM): A Mayo Clinic Experience
    Parrondo, Ricardo
    Das, Saurav
    Hodge, David
    Sledge, Hanna
    Bergsagel, P. Leif
    Fonseca, Rafael
    Leung, Nelson
    Kapoor, Prashant
    Gertz, Morie
    Buadi, Francis
    Dispenzieri, Angela
    Elliott, Jamie
    Fernandez, Andre
    Chanan-Khan, Asher
    Roy, Vivek
    Ailawadhi, Sikander
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S272 - S273
  • [48] Carfilzomib Prescribing Patterns and Outcomes for Relapsed or Refractory Multiple Myeloma (RRMM): A Real-World Analysis
    Dong, Sharlene
    Banerjee, Rahul
    Khan, Adeel
    Wang, Mengru
    Wang, Xiaoliang
    Afghahi, Anosheh
    Afrough, Aimaz
    Janakiram, Murali
    Wang, Bo
    Cowan, Andrew
    Sperling, Adam
    Anderson, Larry
    Rajkumar, S. Vincent
    Kaur, Gurbakhash
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S258 - S259
  • [49] Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Single Center Experience
    Hultcrantz, Malin
    Derkach, Andriy
    Hassoun, Hani
    Korde, Neha
    Maclachlan, Kylee H.
    Mailankody, Sham
    Patel, Dhwani
    Shah, Urvi A.
    Tan, Carlyn
    Akhlaghi, Theresia
    Hamadeh, Issam S.
    Chung, David J.
    Lahoud, Oscar B.
    Landau, Heather
    Scordo, Michael
    Shah, Gunjan L.
    Giralt, Sergio A.
    Lesokhin, Alexander M.
    Usmani, Saad
    BLOOD, 2022, 140 : 7246 - 7248
  • [50] Long-term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5DxCD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
    Rasche, Leo
    Schinke, Carolina
    Touzeau, Cyrille
    Minnema, Monique C.
    van de Donk, Niels W. C. J.
    Rodriguez-Otero, Paula
    Mateos, Maria-Victoria
    Ye, Jing Christine
    Vishwamitra, Deeksha
    Singh, Indrajeet
    Qin, Xiang
    Campagna, Michela
    Masterson, Tara
    Hilder, Brandi W.
    Tolbert, Jaszianne
    Renaud, Thomas
    Heuck, Christoph
    Kane, Colleen
    Chari, Ajai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S561 - S562
12345